Cytovance Biologics Inc. Announces Manufacturing Agreement With Selexys Pharmaceuticals Corporation for Phase II Production of SelG1
11/14/2012 11:17:02 AM
More...
|
Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation (NVS) for Up to $665 Million
9/19/2012 7:29:31 AM
More...
|
Selexys Pharmaceuticals Corporation Completes Phase I Clinical Study for Sickle Cell Drug
12/19/2011 10:51:47 AM
More...
|
Selexys Pharmaceuticals Corporation Initiates Enrollment in Phase I Clinical Study of SelG1
5/4/2011 10:41:28 AM
More...
|
Cytovance Biologics Awarded Biopharmaceutical Development and Manufacturing Contract by Selexys Pharmaceuticals Corporation
4/26/2010 10:04:38 AM
More...
|
Selexys Pharmaceuticals Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)
1/26/2009 9:57:57 AM
More...
|
Selexys Pharmaceuticals Corporation Selects Cytovance Biologics for Process Development Services to Accelerate Development Programs
8/1/2007 10:27:49 AM
More...
|